| Factor |
Telaprevir(N=46) |
Boceprevir(N=26) |
PEG/RBV(N=72) |
P |
| RBV dose adjustment, n (%) |
27(60.0)** |
12(57.1)* |
12(17.9)*,** |
<0.001 |
| PEG dose adjustment, n (%) |
7(16.7) |
3(14.3) |
14(20.9) |
0.74 |
| Lowest Hemoglobin, mean (SD) |
10.3(1.8) |
10.4(1.8) |
11.0(1.8) |
0.061 |
| Anemia grade, n (%) |
|
|
|
0.019 |
| No anemia |
1(2.2)** |
2(7.7) |
6(8.7)** |
|
| Grade 1 |
22(47.8) |
9(34.6) |
44(63.8) |
|
| Grade 2 |
19(41.3) |
12(46.1) |
16(23.2) |
|
| Grade 3 and 4 |
4(8.7) |
1(3.8) |
3(4.3) |
|
| Grade 2-4 Anemia |
23 (50.0)** |
13 (50.0)* |
19 (27.5)*,** |
0.015 |
| EPO use |
9(19.6) |
8(30.7) |
24(33.3) |
0.27 |
| Packed red blood cell transfusion |
7(15.2)** |
3(11.5) |
2(2.8)** |
0.031 |
| Anemia, EPO use and/or blood transfusion, n (%) |
24 (52.2) |
13 (50.0) |
29 (40.3) |
0.4 |
*: Boceprevir arm was significantly different from PEG/RBV arm
**: Telaprevir arm was significantly different from PEG/RBV arm
Abbreviations: n=number of patients, RBV=ribavirin, PEG=peg-interferon,
SD=standard deviation, EPO=erythropoietin alfa |
